Given that normal brain tissue [9, 10], or benign tumours derived from a non-glial lineage (Figures 1A-B) do not express FANCD2, we postulate that inhibition of the FA pathway in high-grade gliomas represents a novel therapeutic window to improve the treatment of these incurable tumours. This evidence concerns the gene FANCD2 and central nervous system cancer.